Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 5/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.30 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.30 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18623934 | 0.83 | KCNN4 (0.35) | HDAC3HDAC1HDAC2HDAC6KCNN4 | |
| SCHEMBL17169474 | 0.83 | KCNN4 (0.35) | HDAC3HDAC1HDAC2HDAC6KCNN4 | |
| SCHEMBL18623932 | 0.77 | HDAC3 (0.33) | HDAC3HDAC1HDAC2HDAC6KCNN4 | |
| SCHEMBL5684701 | 0.77 | TRPA1 (0.42) | HDAC3HDAC1HDAC2HDAC6KCNN4 | |
| SCHEMBL5682311 | 0.76 | KCNN4 (0.42) | HDAC3HDAC1HDAC2HDAC6KCNN4 | |
| SCHEMBL18623914 | 0.75 | — | — | |
| SCHEMBL15904331 | 0.73 | KCNN4 (0.35) | HDAC3HDAC1HDAC2HDAC6KCNN4 | |
| SCHEMBL15904435 | 0.73 | KCNN4 (0.35) | HDAC3HDAC1HDAC2HDAC6KCNN4 | |
| SCHEMBL18636854 | 0.72 | LMNA (0.40) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL17169477 | 0.72 | LMNA (0.40) | HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073337-A1 | DIHYDROTHIAZINE AND DIHYDROOXAZINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073337-A1 | DIHYDROTHIAZINE AND DIHYDROOXAZINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | BACE1, BACE2, APP | HDAC3 1392/4885HDAC1 421/4885HDAC2 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.